Barely Significant
← all excerpts

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.

Sci Rep · 2021 · PMC8560765 · PMID 34725436

Europe PMCDOI
1
hedged sentence
0.2400
closest p · 4.8× alpha
0.2400
boldest claim

The sentences

showed a trendp = 0.24not close (p > 0.1)
They also showed a trend for higher serum levels of a-fetoprotein, which is a diagnostic marker of HCC ( p = 0.24).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.